Ann: Two-Year Results of Phase 1 SR-aGvHD Trial Presented at ISCT, page-4

DOug, we are talking chalk and cheese in terms of trial size and purpose (phase III vs I) but they are undeniably good results using that as a yardstick. My caution in saying more from the sheer vitriol seen on these threads at times.

Its such a shame. CYP and MSB have at times seen posters share wonderful personal insight for the benefit of all investors (its a nightmare keeping abreast of information if you manage your own portfolio, and this one of the benefit of discussion on HC).

Perhaps I do CYP (Hot Copper) investors an injustice and they all know already. But I've seen very little discussion, for example, of the turning tide of IPSC based cell therapies on Hot Copper. A nice article to summarize:

https://bioinformant.com/ipsc-derived-cell-therapeutics/#:~:text=Since%20May%202021%2C%20BlueRock%20Therapeutics,cell%20therapies%20for%20ocular%20diseases.

I digress. Dare I say a promising reported result by CYP in its phase I, GvHD trial?